Stockreport

Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease

Emergent Biosolutions, Inc.  (EBS) 
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm Check Earnings Report
US:NYSE Investor Relations: investors.emergentbiosolutions.com
PDF Human polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-HIG) being developed as a potential treatment for severe hospitalized patients and protection for at-ri [Read more]